Cell Based Immunotherapy Market: Market Size & Forecast 2026

Cell-based immunotherapy encompasses treatments that use engineered or modified living cells, such as CAR-T, TIL, and NK cell therapies, to harness or enhance the immune system's ability to fight cancer and other diseases. The market is currently valued at approximately USD 56.53 billion in 2025 and is expanding at a CAGR of 17.9%, positioning it among the highest-growth therapeutic segments in biopharmaceuticals. The oncology application alone accounts for nearly 30% of total market share, underscoring cancer's dominant role in shaping commercial demand.

• •Global market size in 2025: approximately USD 56.53 billion
• •Projected CAGR: 17.9% through the end of the decade
• •Oncology applications represent roughly 30% of total cell-based immunotherapy revenue

Rising global cancer incidence and the demonstrated efficacy of approved CAR-T therapies in hematologic malignancies are primary growth catalysts. Regulatory momentum, including accelerated FDA approvals and expanded CBER oversight of cellular products, has shortened time-to-market for novel therapies. Increasing investment from pharmaceutical companies, venture capital, and public funding has strengthened manufacturing infrastructure and clinical pipeline depth.

• •Expanding FDA approvals of CAR-T and related cellular products are accelerating commercial adoption
• •Rising global cancer burden and unmet medical need are driving sustained demand
• •Increased capital investment is supporting manufacturing scale-up and clinical development

The market is segmented by therapy type (CAR-T, TIL, NK cell, TCR-T, and others), indication (hematologic vs. solid tumors), and end-user setting (specialty cancer centers, hospitals, and academic institutions). CAR-T cell therapies alone represent a multi-billion-dollar sub-segment, valued at approximately USD 4.6 billion in 2024. North America leads the market due to early regulatory approvals, established reimbursement frameworks, and concentration of advanced treatment centers, while Europe and Asia-Pacific are emerging as high-growth regions supported by expanding clinical trial activity.

• •CAR-T therapies represented a sub-market valued at USD 4.6 billion in 2024
• •Hematologic malignancies account for the largest current share, with solid tumor applications expanding rapidly
• •North America holds the leading regional share, followed by Europe and Asia-Pacific

What are the recent trends and outlook?

The market is shifting from autologous to allogeneic 'off-the-shelf' cell therapies aimed at reducing cost, manufacturing time, and patient wait times. Emerging modalities such as TCR-T, TIL therapies, and engineered NK cells are expanding the addressable patient population beyond B-cell hematologic cancers into solid tumors. Pricing remains a significant challenge, with CAR-T therapies continuing to command premium costs, though scaling production and improved reimbursement frameworks are expected to support broader access through the latter half of the decade.

• •Transition toward allogeneic, off-the-shelf platforms is reshaping manufacturing economics
• •Pipeline expansion into solid tumor indications represents the largest untapped opportunity
• •Cost and reimbursement pressures are driving innovation in delivery models and pricing structures